Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Vaccines: 22 abstracts from GSK’s vaccines pipeline and portfolio have been accepted, including new data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) and Shingrix (Zoster Vaccine ...

60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease • New data to be shared on GSK’s RSV vaccine across ... virus ...

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...

GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.

and the company states that 40% of the world’s children receive a GSK vaccine each year. A key product for the company is Shingrix (recombinant zoster vaccine), which is a vaccine that protects ...

Herpes zoster vaccine Shingrix for shingles has been the main driver of GSK’s revenue growth for some time, accounting for £1.7 billion ($2.1 billion) of the company’s £14 billion in sales ...

Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

In the adult vaccines segment, GSK continues to build on the momentum of its Shingrix Herpes Zoster Vaccine (recombinant, adjuvanted), advancing the adult immunisation category in India through ...